Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer

Figure 3

Breast cancer organoids recapitulate the histological heterogenicity of parental tumors. (a) Bright-field pictures illustrating the temporal change of BC organoid phenotypes. Shown are representative examples of cystic organoids from needle biopsy samples (column on the right), dis-cohesive organoids from surgery samples (middle top) and solid organoids from surgery samples (middle bottom), and dense solid organoids from CSF biopsy samples (right top) and grape-like organoids from CSF biopsy samples (right bottom). Scale bar, 100 μm.(b) Representative H&E and immunohistochemical staining photographs contrast the histology and receptor status of organoids subgroups with the spatial variation in the parent tumor. The ER, PR, and HER2 status of organoid lines generated from BCs is identical to the parent tumor. Scale bar, 50 μm.

(a)

(b)